Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.72 |
| ▸ | ANPEP | P15144 | 8/20 | 0.72 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PEPD | P12955 | 1/20 | 0.40 |
| ▸ | VHL | P40337 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783083 | 1.00 | MMP2 (0.72) | MMP2ANPEPATMALDH1A1MEN1 | |
| SCHEMBL3788774 | 1.00 | MMP2 (0.72) | MMP2ANPEPATMALDH1A1MEN1 | |
| SCHEMBL3788772 | 1.00 | MMP2 (0.72) | MMP2ANPEPATMALDH1A1MEN1 | |
| SCHEMBL3789111 | 1.00 | MMP2 (0.72) | MMP2ANPEPATMALDH1A1MEN1 | |
| SCHEMBL3784082 | 1.00 | MMP2 (0.72) | MMP2ANPEPATMALDH1A1MEN1 | |
| SCHEMBL10793356 | 1.00 | MMP2 (0.72) | MMP2ANPEPATMALDH1A1MEN1 | |
| SCHEMBL996114 | 0.85 | ALDH1A1 (0.59) | MMP2ANPEPATMALDH1A1MEN1 | |
| SCHEMBL8401942 | 0.85 | ALDH1A1 (0.59) | MMP2ANPEPATMALDH1A1MEN1 | |
| SCHEMBL3272061 | 0.85 | ALDH1A1 (0.59) | MMP2ANPEPATMALDH1A1MEN1 | |
| SCHEMBL8401692 | 0.85 | ALDH1A1 (0.59) | MMP2ANPEPATMALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103936644-A | Method for preparing zofenopril calcium | SHANGHAI HAINI PHARMACEUTICAL CO LTD YANGTZE RIVER PHARMACEUTICAL GROUP | 2014-07-23 | — | — | CN | claimed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | ARVINAS OPERATIONS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS (US) | 2014-10-16 | — | — | US | disclosed |
| CN-103936644-A | Method for preparing zofenopril calcium | SHANGHAI HAINI PHARMACEUTICAL CO LTD YANGTZE RIVER PHARMACEUTICAL GROUP | 2014-07-23 | — | — | CN | disclosed |
| US-20120022040-A1 | ANTIMICROBIALS | AMPLYX PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100174096-A1 | Methods for Production of Optically Active Fluoropyrrolidine Derivatives | IM&T RESEARCH, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | disclosed |
| US-7226942-B2 | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226942-B2 | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | BRPF3, STUB1, BRDT | MMP2 2226/4885ANPEP 902/4885ATM 2985/4885 |
| US-20100174096-A1 | Methods for Production of Optically Active Fluoropyrrolidine Derivatives | QDPR, FDPS, DPYD | MMP2 2155/4885ANPEP 491/4885ATM 4690/4885 |
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | API5, BIRC5, BAD | MMP2 2035/4885ANPEP 1414/4885ATM 1240/4885 |
| US-20120022040-A1 | ANTIMICROBIALS | PAM, MPO, OXA1L | MMP2 828/4885ANPEP 75/4885ATM 3232/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | MMP2 3799/4885ANPEP 1757/4885ATM 959/4885 |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | MMP2 2226/4885ANPEP 902/4885ATM 2985/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | MMP2 2226/4885ANPEP 902/4885ATM 2985/4885 |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | MMP2 2226/4885ANPEP 902/4885ATM 2985/4885 |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | MMP2 1769/4885ANPEP 1386/4885ATM 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.